CLINICAL PHARMACOLOGY / SYSTEMATIC REVIEW/META-ANALYSIS
Efficacy and safety of tigecycline doses for ventilator-associated pneumonia caused by multiple resistant bacteria: a systematic review and meta-analysis
More details
Hide details
1
Department of Pharmacy, Zhaoqing First People's Hospital, China
Submission date: 2023-02-07
Final revision date: 2023-04-12
Acceptance date: 2023-04-30
Online publication date: 2023-06-03
Corresponding author
Wendian Zhu
Department of Pharmacy, Zhaoqing First People's Hospital, Zhaoqing, China
Arch Med Sci 2025;21(3):883-888
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Ventilator-associated pneumonia (VAP) caused by multi-resistant bacteria is a serious complication in hospitalized patients. Tigecycline, a broad-spectrum antibiotic, has been suggested as a potential treatment option for this condition, but the optimal dose of tigecycline remains unclear. In this study, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of different doses of tigecycline in the treatment of VAP caused by multi-resistant bacteria.
Material and methods:
To identify relevant studies, we conducted a comprehensive search of multiple databases including the Cochrane Library, Embase, PubMed, the Chinese biomedical literature database, CNKI, Chinese JP, and WP, covering the period up to December 2022. The search strategy was designed to identify studies that evaluated the efficacy and safety of different doses of tigecycline in the treatment of ventilator-associated pneumonia caused by multi-resistant bacteria. We assessed the quality of the included studies using the Jadad quality score, and performed a meta-analysis of the data using Stata software.
Results:
Six articles, consisting of a total of 509 patients, were included, with 280 patients in the control group (low-dose tigecycline) and 229 in the observation group (high-dose tigecycline). There was no clinical heterogeneity or statistical heterogeneity between studies (I2 = 0%, p = 0.80), and a fixed-effect model was used to incorporate the effect size. The clinical effect of the observation group was significantly better than that of the control group (OR = 0.20, 95% CI: 0.13–0.30, p < 0.001). A meta-analysis of the adverse effects showed that there was no clinical heterogeneity or statistical heterogeneity between studies (I2 = 51%, p = 0.10), and a fixed-effect model was used to incorporate the effect size. The incidence of adverse effects in the observed group was similar to that of the control group (OR = 0.96, 95% CI: 0.61–1.50, p = 0.85).
Conclusions:
Duration of high-dose tigecycline treatment for ventilator-related pneumonia caused by multi-resistant bacteria is associated with improved clinical efficacy without an increase in adverse effects. Therefore, it may offer a viable treatment option for patients with ventilator-related pneumonia caused by multi-resistant bacteria.
REFERENCES (20)
1.
Haliloglu M, Bilgili B, Bilginer H, et al. A new scoring system for early diagnosis of ventilator-associated pneumonia: LUPPIS. Arch Med Sci 2020; 16: 1040-8.
2.
Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study. Infez Med 2019; 27: 11-6.
3.
Li Rongkai. Clinical study of tigecycline in the treatment of ventilator-associated pneumonia. J Clin Pulmonary Sci 2019; 24: 857-60.
4.
Dimopoulos G, Almyroudi MP, Kapralos I, et al. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia. Int J Antimicrob Agents 2022; 59: 106487.
5.
Sun P, Tan Y, Liu J, et al. Efficacy of double-dose tigecycline in the treatment of ventilator-associated pneumonia: a meta-analysis. Asian J Surg 2023; 46: 619-20.
6.
Xianjun F, Shasha Z. Efficacy and safety of different doses of tigecycline in treating ventilator-associated pneumonia caused by multi-resistant bacteria. China Practical Med J 2021; 48: 91-4.
7.
Yongyi Z. Efficacy and safety of doubling of the first dose of tigecycline in patients with ventilator-associated pneumonia caused by multiresistant bacteria and its impact on bacterial clearance. Anti-infective Pharm 2020; 17: 910-3.
8.
Lou Y, Shi X. Clinical study of over-dose tigecycline for ventilator-associated pneumonia in multiresistant Gram-negative bacilli. Chin J Emerg Med 2015; 24: 1267-71.
9.
Min F, Meiqi Z, Wenwei CAI. Efficacy and safety study of doubling tigecycline in patients with ventilator-associated pneumonia. Chin J Clin Infect Dis 2016; 9: 416-21.
10.
Zang H, Wang S, Cheng H. Clinical effect of high-dose tigecycline treatment for ventilator-associated pneumonia caused by multi-resistant bacteria. Chin Med 2018; 13: 380-2.
11.
Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine 2020; 99: e19466.
12.
Qin Y, Zhang J, Wu L, et al. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii. Int J Clin Pharmacol Ther 2018; 56: 120-9.
13.
Ye S, Yu J, Zhang C, et al. Application of tigecycline in ventilator-associated pneumonia with Gram-negative bacterial infection in children. Pediatr Emerg Med China 2019; 26: 46-50.
14.
Zha L, Zhang D, Pan L, et al. Tigecycline in the treatment of ventilator-associated pneumonia due to stenotrophomonas maltophilia: a multicenter retrospective cohort study. Infect Dis Ther 2021; 10: 2415-29.
15.
Lin S, Liang L, Zhang C, et al. Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia. J Int Med Res 2020; 48: 300060518760435.
16.
Yu M, Chen Z, Cheng P, et al. Clinical study of tigecycline in the treatment of elderly patients with ventilator-associated pneumonia. Chin J Emerg Med 2019; 28: 1133-8.
17.
Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine 2018; 97: 124-37.
18.
Kuti JL, Kim A, Cloutier DJ, et al. Evaluation of plazomicin, tigecycline, and meropenem pharmacodynamic exposure against carbapenem-resistant enterobacteriaceae in patients with bloodstream infection or hospital-acquired/ventilator-associated pneumonia from the CARE Study (ACHN-490-007). Infect Dis Ther 2019; 8: 383-96.
19.
Farrar JE, Garner KM, Swanson JM, et al. Tigecycline to treat Stenotrophomonas maltophilia ventilator-associated pneumonia in a trauma intensive care unit as a result of a drug shortage: a case series. J Clin Pharm Ther 2020; 45: 836-9.
20.
Bai XR, Jiang DC, Yan SY. High-dose tigecycline in elderly patients with pneumonia due to multidrug-resistant acinetobacter baumannii in intensive care unit. Infect Drug Resist 2020; 18: 1447-54.